Safety and efficacy of 5-aminolevulinic acid phosphate/iron in mild-to-moderate coronavirus disease 2019: A randomized exploratory phase II trial.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
25 Aug 2023
25 Aug 2023
Historique:
medline:
4
9
2023
pubmed:
1
9
2023
entrez:
1
9
2023
Statut:
ppublish
Résumé
5-aminolevulinic acid (5-ALA), a natural amino acid that is marketed alongside sodium ferrous citrate (SFC) as a functional food, blocks severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) proliferation in vitro and exerts anti-inflammatory effects. In this phase II open-label, prospective, parallel-group, randomized trial, we aimed to evaluate the safety and efficacy of 5-ALA in patients with mild-to-moderate coronavirus disease 2019. This trial was conducted in patients receiving 5-ALA/SFC (250/145 mg) orally thrice daily for 7 days, followed by 5-ALA/SFC (150/87 mg) orally thrice daily for 7 days. The primary endpoints were changes in SARS-CoV-2 viral load, clinical symptom scores, and 5-ALA/SFC safety (adverse events [AE] and changes in laboratory values and vital signs). A total of 50 patients were enrolled from 8 institutions in Japan. The change in SARS-CoV-2 viral load from baseline was not significantly different between the 5-ALA/SFC (n = 24) and control (n = 26) groups. The duration to improvement was shorter in the 5-ALA/SFC group than in the control group, although the difference was not significant. The 5-ALA/SFC group exhibited faster improvement rates in "taste abnormality," "cough," "lethargy," and "no appetite" than the control group. Eight AEs were observed in the 5-ALA/SFC group, with 22.7% of patients experiencing gastrointestinal symptoms (decreased appetite, constipation, and vomiting). AEs occurred with 750/435 mg/day in 25.0% of patients in the first phase and with 450/261 mg/day of 5-ALA/SFC in 6.3% of patients in the second phase. 5-ALA/SFC improved some symptoms but did not influence the SARS-CoV-2 viral load or clinical symptom scores over 14 days. The safety of 5-ALA/SFC in this study was acceptable. Further evaluation using a larger sample size or modified method is warranted.
Sections du résumé
BACKGROUND
BACKGROUND
5-aminolevulinic acid (5-ALA), a natural amino acid that is marketed alongside sodium ferrous citrate (SFC) as a functional food, blocks severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) proliferation in vitro and exerts anti-inflammatory effects. In this phase II open-label, prospective, parallel-group, randomized trial, we aimed to evaluate the safety and efficacy of 5-ALA in patients with mild-to-moderate coronavirus disease 2019.
METHODS
METHODS
This trial was conducted in patients receiving 5-ALA/SFC (250/145 mg) orally thrice daily for 7 days, followed by 5-ALA/SFC (150/87 mg) orally thrice daily for 7 days. The primary endpoints were changes in SARS-CoV-2 viral load, clinical symptom scores, and 5-ALA/SFC safety (adverse events [AE] and changes in laboratory values and vital signs).
RESULTS
RESULTS
A total of 50 patients were enrolled from 8 institutions in Japan. The change in SARS-CoV-2 viral load from baseline was not significantly different between the 5-ALA/SFC (n = 24) and control (n = 26) groups. The duration to improvement was shorter in the 5-ALA/SFC group than in the control group, although the difference was not significant. The 5-ALA/SFC group exhibited faster improvement rates in "taste abnormality," "cough," "lethargy," and "no appetite" than the control group. Eight AEs were observed in the 5-ALA/SFC group, with 22.7% of patients experiencing gastrointestinal symptoms (decreased appetite, constipation, and vomiting). AEs occurred with 750/435 mg/day in 25.0% of patients in the first phase and with 450/261 mg/day of 5-ALA/SFC in 6.3% of patients in the second phase.
CONCLUSION
CONCLUSIONS
5-ALA/SFC improved some symptoms but did not influence the SARS-CoV-2 viral load or clinical symptom scores over 14 days. The safety of 5-ALA/SFC in this study was acceptable. Further evaluation using a larger sample size or modified method is warranted.
Identifiants
pubmed: 37653769
doi: 10.1097/MD.0000000000034858
pii: 00005792-202308250-00041
pmc: PMC10470697
doi:
Substances chimiques
Aminolevulinic Acid
88755TAZ87
Iron
E1UOL152H7
Phosphates
0
ferrous citrate
33KM3X4QQW
Types de publication
Randomized Controlled Trial
Clinical Trial, Phase II
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e34858Informations de copyright
Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.
Références
PLoS One. 2023 Feb 9;18(2):e0281399
pubmed: 36757984
Eur J Pharmacol. 2018 Aug 15;833:25-33
pubmed: 29753693
J Diabetes Res. 2019 Nov 6;2019:4267357
pubmed: 31781665
Nature. 2022 Apr;604(7906):553-556
pubmed: 35240676
N Engl J Med. 2021 Nov 18;385(21):1941-1950
pubmed: 34706189
J Appl Microbiol. 2016 Mar;120(3):790-804
pubmed: 26759117
Biochem Biophys Res Commun. 2021 Mar 19;545:203-207
pubmed: 33571909
Int Immunopharmacol. 2016 Aug;37:71-78
pubmed: 26643355
Bone Rep. 2019 Nov 01;11:100228
pubmed: 31763378
Sci Rep. 2018 Jun 28;8(1):9805
pubmed: 29955082
Lancet Infect Dis. 2022 Dec;22(12):e370-e376
pubmed: 36057267
Int Immunopharmacol. 2011 Mar;11(3):358-65
pubmed: 21144919
Biochem Cell Biol. 2004 Jun;82(3):351-9
pubmed: 15181468
Nat Med. 2018 Jun;24(6):802-813
pubmed: 29785027
N Engl J Med. 2022 Apr 14;386(15):1477-1479
pubmed: 35263515
PLoS One. 2021 Jun 10;16(6):e0252964
pubmed: 34111203
N Engl J Med. 2022 Feb 10;386(6):509-520
pubmed: 34914868
N Engl J Med. 2022 Jan 27;386(4):305-315
pubmed: 34937145
Antimicrob Agents Chemother. 2015 Nov;59(11):6960-7
pubmed: 26324278
N Engl J Med. 2021 Dec 2;385(23):e81
pubmed: 34587383
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
N Engl J Med. 2021 Dec 16;385(25):2348-2360
pubmed: 34587382
Diabetes Ther. 2023 Feb;14(2):447-459
pubmed: 36418716
J Infect Dis. 2022 Nov 1;226(9):1593-1607
pubmed: 35429399
N Engl J Med. 2022 Apr 14;386(15):1397-1408
pubmed: 35172054
Congenit Anom (Kyoto). 2020 Sep;60(5):147-148
pubmed: 31872459
J Heart Lung Transplant. 2015 Feb;34(2):254-63
pubmed: 25455753
Virology. 2019 Feb;528:80-88
pubmed: 30580124
BMJ. 2021 Jul 26;374:n1648
pubmed: 34312178
Antimicrob Agents Chemother. 2017 May 24;61(6):
pubmed: 28348154
Sci Bull (Beijing). 2021 May 15;66(9):925-936
pubmed: 33318880
Nucleic Acids Res. 2020 Jun 4;48(10):5254-5267
pubmed: 32329781
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Trop Med Health. 2022 Jan 7;50(1):6
pubmed: 34991723
Front Vet Sci. 2021 Feb 10;8:647189
pubmed: 33644160
BMC Immunol. 2018 Dec 19;19(1):41
pubmed: 30567499
Pathogens. 2022 Jan 27;11(2):
pubmed: 35215109
Biochem Biophys Res Commun. 2016 Feb 19;470(4):900-6
pubmed: 26820535